A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Conditions
Endometrial Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Comprehensive Cancer Center, Duarte, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Medstar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
University of Chicago, Chicago, Illinois, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Maine Medical Center, Scarborough, Maine, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Minnesota, Minneapolis, Minnesota, United States
Washington University School of Medicine Siteman Cancer Center, St Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Englewood Health, Englewood, New Jersey, United States
Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
Roswell Park, Buffalo, New York, United States
Weill Cornell Medicine, New York, New York, United States
Duke University Cancer Center, Durham, North Carolina, United States
University of Oklahoma Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Contact: Study coordinator (Debra Richardson, MD)Contact: Principal Investigator (Debra Richardson, MD)Providence Portland Cancer Institute, Portland, Oregon, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Lifespan - Rhode Island Hospital, Providence, Rhode Island, United States
Baptist Memorial Hospital, Memphis, Tennessee, United States